ing forces on the frozen liver afforded by the closed percutaneous approach in comparison with the open surgical approach. Furthermore, percutaneous liver cryoablation offers advantages relative to other ablation technologies, including excellent ice ball visibility that facilitates precise control of the ablation zone relative to the tumor and critical structures. Finally, in our experience, the use of cryoablation to treat subcapsular liver tumors that require extension of the ablation zone into the adjacent diaphragm or body wall is associated with fewer complications and less postprocedural pain than radiofrequency ablation.
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However, the different mechanisms of inducing cellular death by cryoablation compared with radiofrequency ablation could lead to differences in observed postprocedure imaging features even though both mechanisms ultimately lead to tissue necrosis. Postablation imaging features used to predict local tumor progression are imperfect, in part because of limitations of imaging resolution and postablation changes in the margin [19] .
MRI findings after liver tumor cryoablation have not been fully described with respect to expected postprocedure features or features predictive of local tumor progression [16] [17] [18] [20] [21] [22] . A recent report noted that residual liver tumor enhancement is common on MR images obtained after percutaneous cryoablation in patients without subsequent local tumor progression; however, it has not been established whether the presence or degree of enhancement differs between groups with and without local progression [21] . The objective of this study was to determine which MRI features observed 24 hours after technically successful percutaneous cryoablation of liver tumors predict subsequent local tumor progression and to describe the evolution of imaging findings after cryoablation.
Materials and Methods

Patients and Procedures
This retrospective study was conducted with institutional review board approval and complied with HIPAA. The need for informed consent was waived. Our division's database of percutaneous imaging-guided tumor ablation procedures identified 89 patients who underwent cryoablation of liver tumors between 2005 and 2011. One year of imaging follow-up has been recommended as a minimum to exclude local tumor progression [23] . Thirty-four patients with insufficient imaging follow-up of less than 1 year were excluded. Other exclusion criteria included prior locoregional therapy to the ablated tumor, lack of 24-hour postablation imaging, and incomplete ablation zone coverage of the tumor at 24-hour MRI (Fig. 1) .
Thirty-nine patients (23 men, 16 women; mean age, 52 years; range, 40-85 years) met the inclusion criteria. Nineteen of these patients were included in a previous study focused only on patients without local tumor progression [21] . Twenty-six patients had one tumor, 11 patients had two tumors, and two patients had three tumors treated. Accordingly, 54 liver tumors were analyzed and included hepatocellular carcinoma (n = 8), metastases from colorectal cancer (n = 11), gastrointestinal stromal tumor (n = 10), breast cancer (n = 6), ovarian cancer (n = 4), pancreatic neuroendocrine tumor (n = 4), esophageal cancer (n = 2), liposarcoma (n = 2), melanoma (n = 2), scalp angiosarcoma (n = 2), pancreatic adenocarcinoma (n = 1), tonsillar cancer (n = 1), and thymoma (n = 1). The largest diameters of the tumors ranged from 9 to 63 mm (mean, 30.3 mm; median, 30.0 mm). Tumors were located in Couinaud liver segments II (n = 2), III (n = 4), IVA (n = 4), IVB (n = 3), V (n = 9), VI (n = 10), VII (n = 9), and VIII (n = 13). Tumor cryoablation was performed using CT (n = 37) or MRI (n = 17) guidance. The procedures were performed with IV moderate sedation (n = 12) or general anesthesia (n = 27). One to seven (median, 4) 17-gauge cryoprobes were placed percutaneously for each treated tumor. The cryoprobes were connected to an argon-based cryoablation system (CryoHit, Galil Medical). The ablation protocol used a 15-minute freeze, 10-minute thaw (passive), and 15-minute freeze cycle.
MRI
MRI was performed with one of the following scanners: Signa Excite 1.5 T or HDx 3 T (GE Healthcare) or Magnetom Verio 3 T or Trio 3 T (Siemens Healthcare). Phased-array body coils were used. All examinations included unenhanced, breath-hold, 3D gradient-echo, and T1-weighted acquisitions. Fast spin-echo or turbo spin-echo T2-weighted sequences were also performed. T1-weighted dynamic contrast-enhanced acquisitions were performed in arterial, venous, late venous, and delayed phases. Gadopentetate dimeglumine (Magnevist, Bayer Healthcare) 0.1 mmol/kg (maximum, 10 mmol) was administered IV, followed immediately by a 10-mL saline flush. The arterial phase was defined by hepatic arterial enhancement without hepatic venous enhancement. Venous phase images showed initial enhancement of the hepatic veins. Late venous phase imaging followed the venous phase. The delayed phase was defined by imaging performed at 3 to 9 minutes after contrast material injection.
Image Analysis
Liver MRI examinations performed within 6 weeks before the cryoablation procedures were available to analyze for 42 of 54 tumors. MRI examinations were available to assess all 54 tumors at 24 hours, 35 tumors at 2-4 months, 29 tumors at 5-7 months, and 22 tumors at 8-12 months after cryoablation. Two board-certified radiologists with fellowship training in abdominal imaging and 5 and 21 years of experience after training independently reviewed all MRI examinations using a PACS workstation (Centricity, GE Healthcare). Readers were blinded to all clinical information other than the fact that the patients had undergone percutaneous cryoablation of a liver tumor. Discrepancies were resolved by consensus review. Reviewers were aware of the timing of each scan in relation to the time of cryoablation and reviewed each patient's scans sequentially. Table 1 lists MRI findings that were evaluated as potential predictors of local tumor progression at 24-hour postablation MRI. Visibility of the ablation margin was assessed on unenhanced T1-weighted, T2-weighted, and enhanced T1-weighted images [24] . The ablation margin was considered visible if the margin thickness separating underlying ablated tumor and overlying unablated normal liver could be measured circumferentially on all image slices through the ablation zone [23] . The MRI sequence that best showed the ablation margin was used for margin measurements. Maximum and minimum thicknesses of the ablation margin were measured [25] . For subcapsular tumors, the ablation margin was measured circumferentially even if it extended into adjacent perihepatic soft tissues (Fig. 2) . In five of the 54 tumors in which the ablation margin was not visible in its entirety, the visible portions of the margins were used for measurements. No matter how wide the maximum or average ablation margin, the thinnest margin at any point along the circumference was reported as the minimum margin (Fig. 3) . The presence of a bridging blood vessel at least 3 mm in diameter within the ablation margin contiguous with both underlying tumor and overlying unablated liver at a given point along the ablation margin was noted [26] . 
Initial Postcryoablation MRI
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The subjective predominant signal intensity (SI) of each tumor and the ablation margin on unenhanced T1-weighted and T2-weighted images were noted as hypo-, iso-, or hyperintense relative to normal liver parenchyma [23] . Objective assessment of contrast enhancement was obtained by recording region of interest SI measurements of the ablated tumor, the ablation margin, the periablational liver, and normal liver. SI measurements were obtained from each phase of the dynamic acquisition and compared with unenhanced measurements. Percentage enhancement was calculated using the formula [(SI enhanced − SI unenhanced) / SI unenhanced] × 100. Tumor SI was measured in the visually most enhancing region of the tumor on the phase showing peak enhancement and using the same region for all other phases. A 15% threshold was used to confirm enhancement on the peak tumor enhancement phase [27] . The pattern of tumor enhancement, when it reached this threshold, was assigned one of four possible patterns previously encountered in our practice: homogeneous, inhomogeneous, thin rim, or thick rim (> 2.5 mm). For enhancing tumors, progressive centripetal enhancement was noted if present. Periablational enhancement, if present, was classified into one of the following patterns: transient arterial phase thin rim enhancement, transient arterial phase shunt (usually wedge-shaped or polygonal), and thin or thick (> 3 mm) rim hyperemia in the venous or later phase [19] .
Evaluation of Evolution of MRI Findings
MRI features assessed on the 24-hour study were also assessed on studies at all other available time points (Table 2 ). In addition, the long (D1) and perpendicular (D2) short-axis diameters of the ablation zone were measured on each MRI examination, and the maximum cross-sectional area of the ablation zone was calculated, assuming an ellipse (π /4 × D1 × D2). Percentage changes in cross-sectional area of the ablation zone were calculated at each subsequent time point relative to the 24-hour measurement. Features suggestive of a fibrous capsule, including T1 and T2 hypointensity as well as late enhancement, were noted when present within the periphery of the ablation zone.
Determination of Tumor Recurrence and Progression
The mean duration of imaging follow-up using CT, MRI, or PET/CT was 30.3 months (range, 13-72 months). Progression of imaging findings on follow-up CT, MRI, or PET/CT was used to assess local tumor recurrence and progression at the site of cryoablation. For CT or MRI studies obtained after the 24-hour postablation MRI, any new enhancing nodule or eccentric thickening within or contiguous with the ablation zone and any ablation zone enlargement were considered suspicious for local tumor progression [19, 23, 26] . Any new focal 18 F-FDG uptake on PET/ CT within or adjacent to the ablation margin was considered suspicious also [28] . Suspicious findings were then correlated with all subsequent imaging. Biopsy was not performed in patients with imaging findings of both hepatic and extrahepatic progression that precluded further local therapies. Absence of local progression was defined as a stable or reduced size of the cryoablation zone compared with the 24-hour MRI examination and absence of the suspicious imaging findings described in this paragraph on the basis of imaging follow-up of at least 1 year [23] . Biopsy was not required to confirm the absence of local tumor progression; biopsy procedures were not indicated clinically.
Statistical Analysis
The mean minimum ablation margin thickness and the mean peak percentage tumor enhancement on 24-hour MRI were compared between groups with and without subsequent local tumor progression using the Wilcoxon rank sum test. All other MRI features were compared using the Fisher exact test. All statistical tests were two-sided; p values less than 0.05 were considered significant. The evolution of imaging findings up to 1 year after cryoablation are described in Table 2 for all study tumors as the percentage of tumors showing the finding at each time-point. The dynamic MRI contrast enhancement patterns of all study tumors, ablation margins, periablational zones, and normal liver were depicted graphically as mean percentage enhancement values from MRI examinations obtained before and up to 1 year after cryoablation (Fig. 4) .
Results
Overall, local tumor progression occurred in 14 of 54 (26%) cryoablated tumors. Local progression did not occur in 40 of 54 (74%) cryoablated liver tumors. Five tumors (in five patients) had only intrahepatic local progression and underwent subsequent local therapy, including percutaneous cryoablation of four recurrences and radiofrequency ablation of one. Fine-needle aspiration biopsy confirmed local progression for each of these five tumors. Nine patients had both intrahepatic local tumor progression at the cryoablation site and extrahepatic progression of tumor, which precluded further local therapies.
The ablation margin was distinct from ablated tumor and surrounding unablated liver at 24 hours on at least one MRI sequence, enabling assessment of the entire cryoablation margin in 49 of 54 (90.7%) tumors. Visibility of the entire ablation margin was most reliably detected on dynamic contrast-enhanced images and often visible on T2-weighted and unenhanced T1-weighted images (Table 2) .
Regarding the use of MRI features to predict local progression, the mean minimum ablation margin was 1.9 ± 3.2 mm in ablated tumors with subsequent local progression and 4.9 ± 3.1 mm in those without local progression (p = 0.004) ( Table 1) . Local tumor progression developed in 11 of 26 (42.3%) tumors with a minimum ablation margin less than or equal to 3 mm but only developed in three of 28 (10.7%) tumors with a minimum margin greater than 3 mm (p = 0.012). The odds ratio for progression with a margin less than or equal to 3 mm compared with greater than 3 mm was 6.11 (95% CI,1.28-38.26). A 5-mm threshold for local progression did not achieve statistical significance, however, only two tumors with a minimum margin greater than 5 mm showed local progression. Local progression developed in 11 of 20 (55.0%) tumors with a blood vessel (≥ 3 mm) bridging the ablation margin but only developed in three of 34 (8.8%) tumors without a bridging vessel (p < 0.001) (Fig. 5) . The odds ratio for progression with presence compared with absence of a bridging blood vessel was 12.63 (2.46-81.00). No other 24-hour MRI feature correlated with subsequent local tumor progression. Specifically, 41 of 42 (97.6%) tumors showed contrast 
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enhancement before cryoablation, and 35 of 54 (64.8%) showed enhancement 24 hours after cryoablation. The incidence of tumor enhancement at 24 hours was not significantly different between tumors with or without subsequent local progression (p = 0.75). Persistent enhancement was even more common in the ablation margin than in the cryoablated tumor and also did not correlate with subsequent local tumor progression (p = 0.66).
The evolution of MRI features over time is detailed in Table 2 . Among these, most cryoablated tumors, irrespective of eventual local tumor progression, were hypointense on T1-weighted images and hyperintense on T2-weighted images at 24 hours but became more variable in relative SI at later time points. The ablation margin was almost always hypointense on T1-weighted images and usually hypointense on T2-weighted images at 24 hours, also becoming more variable at later time points (Fig. 6) . The ablation margin became progressively more difficult to visualize at each successive time-point beyond 24 hours.
Tumor enhancement decreased over time but persisted in seven of 22 (31.8%) tumors at 8-12 months, and only two of these seven tumors were associated with local progression. The mean peak percentage enhancement of tumors decreased most prominently 24 hours after cryoablation and continued to decrease thereafter (Fig. 4) . A shift in the phase of peak tumor enhancement from arterial or venous phases before cryoablation to late venous or delayed phases after cryoablation was observed and became more pronounced at each successive follow-up timepoint. A similar shift in peak enhancement phase of the ablation margin to later phases was observed following cryoablation. The mean ablation zone area decreased by 55.6% ± 15.6 at 2-4 months and 63.9% ± 13.1 at 8-12 months. Imaging findings suggestive of a fibrous capsule were observed in 18 of 35 (51.4%) tumors imaged at 3 months after cryoablation, increasing to 14 of 22 (63.6%) at 8-12 months (Fig. 7) .
Discussion
Contrast-enhanced MRI is routinely performed 24 hours after percutaneous liver tumor cryoablation and before discharge at our institution [29] . MRI is used to exclude complications, provide immediate assessment of results, and provide a baseline for future comparisons. Imaging features in this study predictive of subsequent local tumor progression were presence of a blood vessel (≥ 3 mm) bridging the ablation margin or a small (≤ 3 mm) minimum ablation margin. Only two of 54 cryoablated tumors with a minimum ablation margin larger than 5 mm developed subsequent local progression. Therefore, a minimum ablation margin exceeding 5 mm is recommended. 
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Understanding which two liver MRI features are predictive of local tumor progression may help radiologists interpret MRI examinations after percutaneous liver ablations and ultimately identify at an early stage which patients need additional treatment or closer surveillance.
Cryoablation freezes tissues to temperatures less than −20° to −30°C and causes tissue necrosis through mechanisms different from radiofrequency ablation [30] . Direct injury to cell membranes results from intracellular and extracellular ice formation accentuated by repeated freeze-thaw cycles. Indirect cellular damage results from disruption of the vascular endothelium that accentuates thrombosis or reperfusion injury [31] [32] [33] [34] . This study shows that the cryoablated tumor "ghost" is often well visualized on MRI, enabling delineation of the ablation margin on at least one or more MRI sequences. The ablation margin represents the rim of normal liver surrounding the ablated tumor and included in the ablation zone to ensure complete destruction of potential adjacent microscopic tumor.
Radiofrequency ablation is the most widely used liver ablation technology and causes tumor coagulation by heating tissues to temperatures of at least 50-60°C [30] . After radiofrequency ablation, absence of enhancement in completely treated tumors is expected, whereas persistent or new enhancement suggests incomplete treatment [16-18, 20, 35, 36] . The ablation margin is often estimated on MRI or CT images after radiofrequency ablation procedures by comparing the original tumor size and shape with the hypoenhancing ablation zone. Because radiofrequency ablated tumors are indistinct or not visible in 37-71% of ablation zones, it is difficult to identify and accurately report the true minimum ablation margin [37, 38] . This problem has prompted studies using registration techniques of pre-and postablation imaging to improve assessment of the ablation margin [39, 40] . In contradistinction, 24-hour MRI after liver cryoablation appeared to enable complete assessment of the ablation margin in 49 of 54 (90.7%) tumors in this study, enabling the minimum ablation margins to be reported. The dynamic contrast-enhanced T1-weighted acquisition was the most reliable sequence for visualizing the ablation margin, although differences in T1 or T2 SI on unenhanced acquisitions were also helpful ( Table 2 ). The ablation margin typically enhanced less than surrounding unablated liver tissue, particularly in the arterial and venous phases (Fig.  6) . In late venous and delayed phases, enhancement of the margin tended to increase as enhancement in the unablated liver decreased, sometimes resulting in decreased conspicuity of the margin. Visibility of the ablation margin progressively decreased on follow-up MRI.
We previously reported that persistent liver tumor enhancement is common after cryoablation in patients without subsequent local tumor progression, and similar findings have Imaging-Guided Cryoablation of Liver Tumors been described by others after renal tumor cryoablation [21, 41] . This study establishes that persistent enhancement of the tumor and ablation margin after liver cryoablation is common and not statistically different between patients with or without subsequent local tumor progression. The percentage tumor enhancement was also not significantly different between groups. Persistent tumor and ablation margin enhancement sometimes included reperfused blood vessels that coursed into and out of the ablation zone. Freeze injury of blood vessels may lead to vasodilation and leakiness, which, along with reperfusion, may account for the observed contrastenhancement findings. For example, tumor enhancement after cryoablation tended to peak in later dynamic phases than was observed before cryoablation. Reperfusion of the cryoablation zone also explains the occasional observation of centripetal enhancement of the cryoablation zone on dynamic acquisitions. Persistent tumor or ablation margin enhancement that occurred in the absence of local tumor progression was invariably present at 24 hours and did not initially appear on subsequent follow-up MRI. The cryoablation zone involuted rapidly over time, with a mean decrease of 55.6% in cross-sectional area at 2-4 months. The involution often appeared proportionately greater in the ablation margin than in the ablated tumor, although this was not quantified. Accordingly, the ablation margin is ideally evaluated on 24-hour MRI because subsequent involution makes assessment of the margin progressively more difficult. Enhancement in the rim of liver surrounding the ablation zone, referred to as "benign periablational enhancement," was commonly seen after cryoablation, as it is after radiofrequency ablation, either as a thin rim of hyperemia in the arterial phase or as a thick halo in the venous phase [42] . As with radiofrequency ablation, arterial phase transient shunt enhancement was also often noted around cryoablation zones.
We occasionally observed a peripheral ring of enhancement within the ablation margin that might simulate benign periablational enhancement. Periablational enhancement, however, occurs in the unablated liver tissue immediately peripheral to the ablation margin (Fig. 3) . As early as 3 months after cryoablation, a rim of enhancement can be seen that suggests a developing fibrous capsule defining the outer limits of the cryoablation zone. The presumed fibrous capsule develops within the peripheral part of the ablation margin. The key features suggesting a fibrous capsule were T1 and T2 hypointensity and contrast enhancement that first appeared or persisted on delayed phases (Fig.  7) . Periablational enhancement, on the other hand, corresponded to viable tissue that was not T1 and T2 hypointense and enhanced early or transiently. Distinguishing a fibrous capsule from periablational enhancement is likely to be important in defining the actual boundary of the ablation zone. The fibrous capsule may further prove useful in that we have not observed tumor recurring in or inside of a fibrous capsule.
The retrospective nature of this study imposed certain limitations, including the use of multiple MRI scanners and sequence parameters that could have affected the imaging findings. Diffusion-weighted imaging was not routinely performed during the study period and therefore is not included 
in this analysis. Some patients did not undergo follow-up MRI studies at each time point beyond the initial 24-hour postprocedure study, and that limited the analysis of time-points beyond 24 hours. MRI findings at 8-12 months could potentially have been affected by repeat ablation procedures of three study tumors. Dynamic or temporal changes in contrast enhancement were not analyzed as predictors of local progression. Results were not analyzed by histologic tumor subtype because a much larger study would be required to yield statistically significant data. The absence of local tumor progression was established on the basis of at least 1 year of imaging follow-up, and pathology (biopsy or surgical resection) could not be justified clinically in these patients. Additionally, follow-up imaging modalities used to confirm progression or lack of progression included CT, MRI, or PET/CT in various combinations because of the retrospective nature of this study. The MRI assessment of the ablation margin relied on SI differences between ablated tumor, the ablation margin, and surrounding unablated liver; however, histopathologic confirmation of the imaging assessment of the ablation margin was not possible. Finally, it should be emphasized that our study was not intended to compare the performance of liver cryoablation with other ablation technologies. Rather, our study results may assist radiologists who perform liver cryoablation procedures or who interpret the follow-up imaging studies used to guide subsequent patient care.
In conclusion, liver tumor enhancement on MRI after percutaneous cryoablation is common and alone does not indicate inadequate treatment; however, a small (≤ 3 mm) minimum ablation margin or the presence of a blood vessel (≥ 3 mm) bridging the ablation margin are each predictive of local progression.
